What is Caidya?
Caidya operates as a comprehensive partner for global innovators, providing end-to-end clinical services that span the entire drug development lifecycle. From pre-IND strategy and clinical development to regulatory submission and post-marketing surveillance, the firm distinguishes itself through a focus on delivery excellence and trial transparency. By integrating industry-leading clinical technology, Caidya empowers its partners to make data-driven decisions, effectively navigating the complexities of modern therapeutic research. The company's market position is defined by its ability to bridge the gap between complex clinical requirements and efficient, high-quality execution.
How much funding has Caidya raised?
Caidya has raised a total of $297.8M across 14 funding rounds:
Debt
$13M
Debt
$3M
Debt
$4M
Private Equity
$50M
Private Equity
$3.7M
Debt
$3M
Private Equity
$10M
Debt
$18.4M
Debt
$2M
Other Financing Round
$165M
Debt (2012): $13M, investors not publicly disclosed
Debt (2014): $3M with participation from Undisclosed
Debt (2014): $4M, investors not publicly disclosed
Private Equity (2015): $50M supported by Hatteras Venture Partners, Crestline Investors, Inc., and Virgo Investment Group, LLC
Private Equity (2016): $3.7M, investors not publicly disclosed
Debt (2017): $3M backed by Undisclosed
Private Equity (2017): $10M, investors not publicly disclosed
Debt (2020): $18.4M, investors not publicly disclosed
Debt (2020): $2M supported by PPP
Other Financing Round (2025): $165M featuring Rubicon Founders
Key Investors in Caidya
Rubicon Founders
Rubicon Founders is an entrepreneurial healthcare investment firm dedicated to building and growing transformational companies that deliver enduring value in the healthcare sector.
Hatteras Venture Partners
A venture capital firm specializing in early-stage life science companies, focusing on biopharmaceuticals, medical devices, and diagnostics.
Morgan Stanley
A global financial services leader providing investment banking, securities, and wealth management services to a diverse client base.
What's next for Caidya?
With the recent influx of capital, Caidya is well-positioned to accelerate its growth trajectory within the competitive CRO landscape. The strategic focus will likely center on expanding its therapeutic expertise and further refining its proprietary digital platforms to ensure superior trial outcomes. As the firm continues to support global innovators, this latest financing round provides the necessary liquidity to scale operations, invest in talent acquisition, and maintain its competitive edge in the rapidly evolving life sciences sector. The company remains focused on delivering enduring value to its partners while revolutionizing the standards of clinical research delivery.
See full Caidya company page
